ArticleHaematologica2016
Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference.
Abstract readLetter
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.Blood advances · 2026Article
- Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.British journal of haematology · 2025Review
- Chromoanagenesis Detection in Chronic Lymphocytic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Article
- Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL).Cancers · 2022Article
- Review
- Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations.HemaSphere · 2022Article
- The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.Haematologica · 2022Article
- Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.Haematologica · 2022Article
- The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.Cancers · 2021Review
- Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype.Frontiers in oncology · 2021Review
- CytoGPS: A large-scale karyotype analysis of CML data.Cancer genetics · 2020Article
- Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.Haematologica · 2020Review
- Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.Biomarker research · 2020Review
- The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.British journal of cancer · 2019Article
- Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.Blood · 2019Article
- Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia.Oncotarget · 2018Review
- Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence ofOncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Panagiotis BaliakasDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Anna PuiggrosLaboratori de Citogenètica Molecular Servei de Patologia Hospital del Mar, Barcelona, Spain Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Program, IMIM-Hospital del Mar, Barcelona, Spain.
Aliki XochelliDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Lesley-Ann SuttonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Florence Nguyen-KhacAP-HP, Pitie-Salpetriere Hospital, Department of Hematology, and UPMC Univ Paris 06, UMRS 1138, France.
Anne GardinerDepartment of Haematology, Royal Bournemouth Hospital, UK.
Karla PlevovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Eva MingaInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Anastasia HadzidimitriouInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Renata WalewskaDepartment of Haematology, Royal Bournemouth Hospital, UK.
Helen McCarthyDepartment of Haematology, Royal Bournemouth Hospital, UK.
Margarita OrtegaHospital Universitari Vall d'Hebron, Barcelona, Spain.
Rosa ColladoConsorcio Hospital General Universitario de Valencia, Spain.
Teresa GonzálezFundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
Isabel GranadaInstitut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital GeransTrias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Elisa LuñoHospital Universitario Central de Asturias, Oviedo, Spain.
Jana KotaškováCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Theodoros MoysiadisInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Zadie DavisDepartment of Haematology, Royal Bournemouth Hospital, UK.
Niki StavroyianniHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Achilles AnagnostopoulosHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Jonathan C StreffordCancer Sciences, Faculty of Medicine, University of Southampton, UK.
Sarka PospisilovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Frederic DaviAP-HP, Pitie-Salpetriere Hospital, Department of Hematology, and UPMC Univ Paris 06, UMRS 1138, France.
Anastasia AthanasiadouHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Richard RosenquistDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
David OscierDepartment of Haematology, Royal Bournemouth Hospital, UK.
Blanca EspinetLaboratori de Citogenètica Molecular Servei de Patologia Hospital del Mar, Barcelona, Spain Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Program, IMIM-Hospital del Mar, Barcelona, Spain.
Kostas StamatopoulosDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden Institute of Applied Biosciences, CERTH, Thessaloniki, Greece kostas.stamatopoulos@gmail.com.
Funding
Cancer Research UK C34999/A18087
Abstract
PubMed holds no abstract for this paper.
Indexed as
Polymorphism, Single NucleotideChromosomes, Human, Pair 12FemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleTrisomybio-engineeredcord bloodmetabolic profilenativeRBC
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.